RANCHO CORDOVA, Calif.,
Jan. 7, 2021 /PRNewswire/
-- ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market
leader in automated cell processing tools and services in the cell
and gene therapy field, today announced that Jeff Cauble, Chief Financial Officer, will
present a company overview at the H.C. Wainwright BIOCONNECT 2021
The presentation will be available beginning January 11, at 6:00 am
ET, on the ThermoGenesis website at:
and will be archived for a period of 90 days after the
About ThermoGenesis Holdings, Inc.
Holdings, Inc. develops, commercializes, and markets a range of
automated technologies for CAR-T and other cell-based therapies.
The Company currently markets a full suite of solutions for
automated clinical biobanking, point-of-care applications, and
automation for immuno-oncology, including its semi-automated,
functionally-closed CAR-TXpress™ platform, which streamlines
the manufacturing process for the emerging CAR-T immunotherapy
market. For more information about ThermoGenesis, please
Paula Schwartz, Rx
SOURCE ThermoGenesis Holdings, Inc.